Mapping the Longitudinal, Multidimensional Impact of MS in Relation to Variables Indicative of Neurological Reserve - Trial NCT06410326
Access comprehensive clinical trial information for NCT06410326 through Pure Global AI's free database. This phase not specified trial is sponsored by National MS Center Melsbroek and is currently Completed. The study focuses on Multiple Sclerosis. Target enrollment is 2600 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Observational
Sponsor & Location
National MS Center Melsbroek
Timeline & Enrollment
N/A
Apr 01, 2024
Apr 01, 2024
Primary Outcome
EDSS,Functional tests,Cognitive tests,The EQ-Visual Analog Score (EQ-VAS)
Summary
Some MS patients quickly accumulate neurological deficits, while others remain well for
 decades. Even though associations with age, sex, health behaviors, comorbidities and social
 determinants of health are widely acknowledged, the clinical heterogeneity in MS is poorly
 understood and variables with a robust prognostic value are lacking. Recent data suggest a
 key role for resilience in the central nervous system, potentially supporting the concept of
 neurological reserve in MS.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06410326
Non-Device Trial